Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...
Massachusetts families are still struggling to find alternatives almost a year after GlaxoSmithKline canceled a widely ...
At GlaxoSmithKline, we never lose sight of the fact that patients are at the core of what we do and that millions of lives are impacted by cancer. The patient’s voice is at the heart of our ...
UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...
With vaccine hesitancy leading to a rise in measles cases, the FDA's approval of GlaxoSmithKline's venerable vaccine Priorix for sale in the US looks timely. Priorix was first launched in Europe ...
British drugmaker AstraZeneca has appointed a new China head, replacing a former executive who has been detained by ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was ...
GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together. The Company is ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Graham Parry, an analyst from Bank of America Securities, maintained the Sell rating on GlaxoSmithKline (GSK – Research Report). The associated ...